Genetic prediction of renal transplant outcome

Current Opinion in Nephrology and Hypertension

Volumn 17, Issue 6, 2008, Pages 573-579

  Goldfarb Rumyantzev, Alexander S ^a   Naiman, Natalie ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Acute rejection; Genetics; Kidney transplant; Outcome

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALDOSTERONE SYNTHASE; AZATHIOPRINE; CHEMOKINE RECEPTOR CCR2; COMPLEMENT COMPONENT C3; CYCLOSPORIN; CYTOCHROME P450 3A5; CYTOKINE; GAMMA INTERFERON; HEME OXYGENASE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OSTEONECTIN; PROTEIN P53; RANTES; SLC30A8 PROTEIN; TACROLIMUS; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VITAMIN D RECEPTOR; ZINC TRANSPORTER;

ACUTE GRAFT REJECTION; BONE MARROW TOXICITY; CHRONIC ALLOGRAFT NEPHROPATHY; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG METABOLISM; GENETIC POLYMORPHISM; GENOTYPE; GINGIVA HYPERPLASIA; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; PHARMACOGENOMICS; PREDICTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SAMPLE SIZE; SKIN CANCER; SQUAMOUS CELL CARCINOMA;

ACUTE DISEASE; BIOMEDICAL RESEARCH; CYTOKINES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNITY, INNATE; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME;

EID: 56249089725     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32830f4579     Document Type: Review

References (73)

1. Perico N, Ruggenenti P, Scalamogna M, Remuzzi G. Tackling the shortage of donor kidneys: how to use the best that we have. Am J Nephrol 2003; 23:245-259.
2. Eggers P. Comparison of treatment costs between dialysis and transplantation. Semin Nephrol 1992; 12:284-289.
3. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341:1725-1730.
4. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55:752-756; discussion 756-757.
5. Kamoun M. Cellular and molecular parameters in human renal allograft rejection. Clin Biochem 2001; 34:29-34.
6. Massy ZA, Guijarro C, Wiederkehr MR, et al. Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. Kidney Int 1996; 49:518-524.
7. Matas AJ, Gillingham KJ, Payne WD, Najarian JS. The impact of an acute rejection episode on long-term renal allograft survival (11/2). Transplantation 1994; 57:857-859.
8. Ramanathan V, Goral S, Helderman JH. Renal transplantation. Semin Nephrol 2001; 21:213-219.
9. Shoskes DA, Cecka JM. Deleterious effects of delayed graft function in cadaveric renal transplant recipients independent of acute rejection. Transplantation 1998;66:1697-1701.
10. Mahalati K, Belitsky P, Sketris I, et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999; 68:55-62.
11. Nickerson P, Jeffery J, Gough J, et al. Effect of increasing baseline immuno-suppression on the prevalence of clinical and subclinical rejection: a pilot study. J Am Soc Nephrol 1999; 10:1801-1805.
12. van Saase JL, van der Woude FJ, Thorogood J, et al. The relation between acute vascular and interstitial renal allograft rejection and subsequent chronic rejection. Transplantation 1995; 59:1280-1285.
13. Flechner SM, Kurian SM, Head SR, et al. Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes. Am J Transplant 2004; 4:1475-1489.
14. Sarwal M, Chua MS, Kambham N, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003; 349:125-138.
15. McKenna RM, Lee KR, Gough JC, et al. Matching for private or public HLA epitopes reduces acute rejection episodes and improves two-year renal allograft function. Transplantation 1998; 66:38-43.
16. Dallman MJ. Cytokines as mediators of organ graft rejection and tolerance. Curr Opin Immunol 1993; 5:788-793.
17. Alakulppi NS, Kyllonen LE, Jantti VT, et al. Cytokine gene polymorphisms and risks of acute rejection and delayed graft function after kidney transplantation. Transplantation 2004; 78:1422-1428.
18. Hahn AB, Kasten-Jolly JC, Constantino DM, et al. TNF-alpha, IL-6, IFN-gamma, and IL-10 gene expression polymorphisms and the IL-4 receptor alpha-chain variant Q576R: effects on renal allograft outcome. Transplantation 2001; 72:660-665.
19. McDaniel DO, Barber WH, Nguyan C, et al. Combined analysis of cytokine genotype polymorphism and the level of expression with allograft function in African-American renal transplant patients. Transpl Immunol 2003; 11:107-119.
20. Pelletier R, Pravica V, Perrey C, et al. Evidence for a genetic predisposition towards acute rejection after kidney and simultaneous kidney-pancreas transplantation. Transplantation 2000; 70:674-680.
21. Poli F, Boschiero L, Giannoni F, et al. Tumour necrosis factor-alpha gene polymorphism: implications in kidney transplantation. Cytokine 2000; 12: 1778-1783.
22. Sankaran D, Asderakis A, Ashraf S, et al. Cytokine gene polymorphisms predict acute graft rejection following renal transplantation. Kidney Int 1999; 56:281-288.
23. Shahbazi M, Fryer AA, Pravica V, et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002; 13:260-264.
24. Tinckam K, Rush D, Hutchinson I, et al. The relative importance of cytokine gene polymorphisms in the development of early and late acute rejection and six-month renal allograft pathology. Transplantation 2005; 79:836-841.
25. Dmitrienko S, Hoar DI, Balshaw R, Keown PA. Immune response gene polymorphisms in renal transplant recipients. Transplantation 2005; 80:1773-1782.
26. Loucaidou M, Stitchbury J, Lee J, et al. Cytokine polymorphisms do not influence acute rejection in renal transplantation under tacrolimus-based immunosuppression. Transplant Proc 2005; 37:1760-1761.
27. Marshall SE, McLaren AJ, Haldar NA, et al. The impact of recipient cytokine genotype on acute rejection after renal transplantation. Transplantation 2000; 70:1485-1491.
28. Grinyo J, Vanrenterghem Y, Nashan B, et al. Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int 2008 [Epub ahead of print].
29. Azarpira N, Aghdaie MH, Geramizadeh B, et al. Cytokine gene polymorphisms in renal transplant recipients. Exp Clin Transplant 2006; 4:528-531.
30. Brabcova I, Petrasek J, Hribova P, et al. Genetic variability of major inflammatory mediators has no impact on the outcome of kidney transplantation. Transplantation 2007; 84:1037-1044. This review is based on a reasonably large sample size; authors used appropriate statistical techniques, protocol biopsy in a subpopulation of patients. Authors studied nine SNPs with negative results. The discussion section of the review describes potential pitfalls of genetic studies.
31. Breulmann B, Bantis C, Siekierka M, et al. Influence of cytokine genes polymorphisms on long-term outcome in renal transplantation. Clin Transplant 2007; 21:615-621. Four specific polymorphisms were studied in association with acute rejection, renal function, and long-term outcome in a single-center study of 224 renal transplant recipients with negative results. Authors used reasonable sample size (only recipients were genotyped) and appropriate analytical techniques.
32. Alakulppi NS, Kyllonen LE, Partanen J, et al. Lack of association between thrombosis-associated and cytokine candidate gene polymorphisms and acute rejection or vascular complications after kidney transplantation. Nephrol Dial Transplant 2008; 23:364-368. This is a negative single-center study of the association between specific recipient and donor polymorphisms and short-term outcome (acute rejection and vascular events). Authors studied 772 deceased donor transplantations.
33. Manchanda PK, Bid HK, Kumar A, Mittal RD. Genetic association of inteneukin1beta and receptor antagonist (IL-IRa) gene polymorphism with allograft function in renal transplant patients. Transpl Immunol 2006; 15:289-296.
34. Satoh S, Saito M, Inoue K, et al. Association of cytokine polymorphisms with subclinical progressive chronic allograft nephropathy in Japanese renal transplant recipients: preliminary study, Int J Urol 2007; 14:990-994.
35. Bamoulid J, Courivaud C, Deschamps M, et al. IL-6 promoter polymorphism 174 is associated with new-onset diabetes after transplantation. J Am Soc Nephrol 2006; 17:2333-2340.
36. Hoffmann TW, Halimi JM, Buchler M, et al. Association between a polymorphism in the IL-12p40 gene and cytomegalovirus reactivation after kidney transplantation. Transplantation 2008; 85:1406-1411.
37. Kolesar L, Novota P, Krasna E, et al. Polymorphism of interleukin-18 promoter influences the onset of kidney graft function after transplantation. Tissue Antigens 2007; 70:363-368.
38. Gunesacar R, Opelz G, Erken E, et al. VEGF 936 C/T gene polymorphism in renal transplant recipients: association of the T allele with good graft outcome. Hum Immunol 2007; 68:599-602.
39. Kruger B, Boger CA, Obed A, et al. RANTES/CCL5 polymorphisms as a risk factor for recurrent acute rejection. Clin Transplant 2007; 21:385-390. Three polymorphisms were studied in RANTES chemokine gene with largely negative results in 261 recipients of the first renal transplant.
40. Tajik N, Salari F, Ghods AJ, et al. Association between recipient ICAM-1 K469 allele and renal allografl acute rejection. Int J Immunogenet 2008; 35:9-13.
41. Palmer SM, Burch LH, Mir S, et al. Donor polymorphisms in Toll-like receptor-4 influence the development of rejection after renal transplantation. Clin Transplant 2006; 20:30-36.
42. Ducloux D, Deschamps M, Yannaraki M, et al. Relevance of Toll-like receptor-4 polymorphisms in renal transplantation. Kidney Int 2005; 67:2454-2461.
43. Cervera C, Lozano F, Saval N, et al. The influence of innate immunity gene receptors polymorphisms in renal transplant infections. Transplantation 2007; 83:1493-1500.
44. Kang SW, Park SJ, Kim YW, et al. Association of MCP-1 and CCR2 polymorphisms with the risk of late acute rejection after renal transplantation in Korean patients, Int J Immunogenet 2008; 35:25-31. Authors studied the polymorphisms in the gene of MCP-1 and its corresponding receptor, CCR2, in 167 Korean recipients and showed an association between particular polymorphisms and acute rejection. This study demonstrates the potential interaction between polymorphisms of the two genes studied. Although this study used multivariate analysis with adjustment for potential confounders, the adjustment for multiple comparisons has not been done.
45. Zhang G, Wang H, Wang F, et al. Gene polymorphisms of the reninangiotensin-aldosterone system and angiotensin II type 1 -receptor activating antibodies in renal rejection. Tohoku J Exp Med 2007; 213:203-214.
46. Azarpira N, Bagheri M, Raisjalali GA, et al. Angiotensinogen, angiotensin-converting enzyme and plasminogen activator inhibitor-1 gene polymorphism in chronic allograft dysfunction. Mol Biol Rep 2008 [Epub ahead of print].
47. Ayed K, Ayed-Jendoubi S, Ben Abdallah T, et al. Polymorphism of the renin-angiotensin-aldosterone system in patients with chronic allograft dysfunction. Transpl Immunol 2006; 15:303-309.
48. Wang J, Yang JW, Zeevi A, et al. IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther 2008; 83:711-717. In this study based on 191 transplant recipients on mycophenolate mofetil, authors demonstrated that polymorphism in the IMPDH1 gene was associated with acute rejection during the first year. Authors postulated that the polymorphism in question is associated with mycophenolate mofetil response.
49. Hesselink DA, van Schaik RH, van Agteren M, et al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics 2008; 18:339-348.
50. Brown KM, Kondeatis E, Vaughan RW, et al. Influence of donor C3 allotype on late renal-transplantation outcome. N Engl J Med 2006; 354:2014-2023.
51. Courtney AE, McNamee PT, Middleton D, et al. Association of functional heme oxygenase-1 gene promoter polymorphism with renal transplantation outcomes. Am J Transplant 2007; 7:908-913.
52. Turpeinen H, Kyllonen LE, Parkkinen J, et al. Heme oxygenase 1 gene polymorphisms and outcome of renal transplantation. Int J Immunogenet 2007; 34:253-257.
53. Leite JL, Manfrinatto JA, Mazzali M, Ward LS. Polymorphisms at exon 4 of p53 and the susceptibility to herpesvirus types 6 and 1 infection in renal transplant recipients. Transpl Int 2006; 19:732-737.
54. Kang ES, Kim MS, Kim YS, et al. A polymorphism in the zinc transporter gene SLC3QA8 confers resistance against posttransplantation diabetes mellitus in renal allogratt recipients. Diabetes 2008; 57:1043-1047.
55. Laing ME, Dicker P, Moloney FJ, et al. Association of methylenetetrahydro-folate reductase polymorphism and the risk of squamous cell carcinoma in renal transplant patients. Transplantation 2007; 84:113-116.
56. Drozdzik A, Kurzawski M, Kozak M, et al. SPARC gene polymorphism in renal transplant patients with gingival overgrowth. J Periodontol 2007; 78:2185-2189.
57. Abdi R, Tran TB, Sahagun-Ruiz A, et al. Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol 2002; 13:754-758.
58. Hesselink DA, van Gelder T. Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Clin Pharmacol Ther 2005; 78:317-321.
59. Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14:147-154.
60. Mourad M, Mourad G, Wallemacq P, et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 2005; 80:977-984.
61. Roy JN, Barama A, Poirier C, et al. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics 2006; 16:659-665.
62. Tada H, Tsuchiya N, Satoh S, et al. Impact of CYP3A5 and MDR1 (ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc 2005; 37:1730-1732.
63. Anglicheau D, Le Corre D, Lechaton S, et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant 2005; 5:595-603.
64. Kurzawski M, Dziewanowski K, Gawronska-Szklarz B, et al. The impact of thiopurine s-methyltransferase polymorphism on azathioprine-induced myelo-toxicity in renal transplant recipients. Ther Drug Monit 2005; 27:435-441.
65. Ozdemir FN, Micozkadioglu H, Atac FB, et al. The renin-angiotensin system and endothelial nitric oxide synthase gene polymorphisms and cyclosporine toxicity in renal transplant patients. Transplant Proc 2004; 36:128-130.
66. Asano T, Takahashi KA, Fujioka M, et al. Genetic analysis of steroid-induced osteonecrosis of the femoral head. J Orthop Sci 2003; 8:329-333.
67. Argani H, Noroozianavval M, Aghaeishahsavari M, et al. Renin-angiotensin system polymorphisms and renal graft function in renal transplant recipients. Saudi Med J 2007; 28:1496-1502.
68. Muller V, Molnar Z, Szabo AJ. Single nucleotide polymorphism: is it only genetic palmistry? Transplantation 2007; 84:954-955.
69. Lee H, Clark B, Gooi HC, et al. Influence of recipient and donor IL-1 alpha, IL-4, and TNFalpha genotypes on the incidence of acute renal allograft rejection. J Clin Pathol 2004; 57:101-103.
70. Daly AK. Individualized drug therapy. Curr Opin Drug Discov Devel 2007; 10:29-36.
71. Benavides CA, Pollard VB, Mauiyyedi S, et al. BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes. Transplantation 2007; 84:83-88.
72. Bosmans JL, Verpooten GA. Malignancy after kidney transplantation: still a challenge. Kidney Int 2007; 71:1197-1199.
73. Maalouf NM, Shane E. Osteoporosis after solid organ transplantation. J Clin Endocrinol Metab 2005; 90:2456-2465.